Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland

2 years ago

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano,…

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

2 years ago

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and…

T-Therapeutics appoints Dr David Hung as Chairman

2 years ago

T-Therapeutics appoints Dr David Hung as Chairman Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development…

Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc.

2 years ago

Company announcement, Helsinki, 12 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Provides Further Details on Technology License…

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

2 years ago

Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team…

BioSenic to host Annual General Meeting on July 12, 2024

2 years ago

PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert,…

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

2 years ago

SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading…

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

2 years ago

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage…

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

2 years ago

Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD…

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

2 years ago

PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative…